An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: A randomised controlled trial

Diab Vasc Dis Res. 2017 Jul;14(4):336-344. doi: 10.1177/1479164117698918. Epub 2017 Mar 21.

Abstract

Aim: To evaluate an additional rapid-acting insulin bolus on postprandial lipaemia, inflammation and pro-coagulation following high-carbohydrate high-fat feeding in people with type 1 diabetes.

Methods: A total of 10 males with type 1 diabetes [HbA1c 52.5 ± 5.9 mmol/mol (7.0% ± 0.5%)] underwent three conditions: (1) a low-fat (LF) meal with normal bolus insulin, (2), a high-fat (HF) meal with normal bolus insulin and (3) a high-fat meal with normal bolus insulin with an additional 30% insulin bolus administered 3-h post-meal (HFA). Meals had identical carbohydrate and protein content and bolus insulin dose determined by carbohydrate-counting. Blood was sampled periodically for 6-h post-meal and analysed for triglyceride, non-esterified-fatty acids, apolipoprotein B48, glucagon, tumour necrosis factor alpha, fibrinogen, human tissue factor activity and plasminogen activator inhibitor-1. Continuous glucose monitoring captured interstitial glucose responses.

Results: Triglyceride concentrations following LF remained similar to baseline, whereas triglyceride levels following HF were significantly greater throughout the 6-h observation period. The additional insulin bolus (HFA) normalised triglyceride similarly to low fat 3-6 h following the meal. HF was associated with late postprandial elevations in tumour necrosis factor alpha, whereas LF and HFA was not. Fibrinogen, plasminogen activator inhibitor-1 and tissue factor pathway levels were similar between conditions.

Conclusion: Additional bolus insulin 3 h following a high-carbohydrate high-fat meal prevents late rises in postprandial triglycerides and tumour necrosis factor alpha, thus improving cardiovascular risk profile.

Keywords: Type 1 diabetes; cardiovascular risk; high-fat feeding; inflammation; lipaemia.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Blood Coagulation / drug effects
  • Blood Glucose / drug effects*
  • Blood Glucose / metabolism
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diet, High-Fat*
  • Dietary Carbohydrates / administration & dosage
  • Dietary Carbohydrates / metabolism*
  • Dietary Fats / administration & dosage
  • Dietary Fats / metabolism*
  • England
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Inflammation Mediators / blood
  • Insulin Detemir / administration & dosage*
  • Insulin Glargine / administration & dosage*
  • Male
  • Meals*
  • Postprandial Period*
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Triglycerides / blood
  • Tumor Necrosis Factor-alpha / blood
  • Young Adult

Substances

  • Biomarkers
  • Blood Glucose
  • Dietary Carbohydrates
  • Dietary Fats
  • Hypoglycemic Agents
  • Inflammation Mediators
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • Insulin Glargine
  • Insulin Detemir